m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00538)
Target Name HPK/GCK-like kinase HGK (MAP4K4)
Synonyms
HPK/GCK-like kinase HGK; MAPK/ERK kinase kinase kinase 4; MEK kinase kinase 4; MEKKK 4; Nck-interacting kinase
    Click to Show/Hide
Gene Name MAP4K4
Chromosomal Location 2q11.2
Family Protein kinase superfamily, STE Ser/Thr protein kinase family, STE20 subfamily
Function
Serine/threonine kinase that may play a role in the response to environmental stress and cytokines such as TNF-alpha. Appears to act upstream of the JUN N-terminal pathway. Phosphorylates SMAD1 on Thr-322.
    Click to Show/Hide
Gene ID 9448
Uniprot ID
M4K4_HUMAN
HGNC ID
HGNC:6866
Ensembl Gene ID
ENSG00000071054
KEGG ID
hsa:9448
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
MAP4K4 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
YTH domain-containing family protein 2 (YTHDF2) [READER]
 Regulator Info 
In total 2 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary YTHDF2 regulates the stability of MAP2K4 and HPK/GCK-like kinase HGK (MAP4K4) mRNAs.This study identified that dasatinib and quercetin alleviate LPS-induced senescence in HUVECs via the TRAF6-MAPK-NF-Kappa-B axis in a YTHDF2-dependent manner, providing novel ideas for clinical treatment of age-related cardiovascular diseases.
Responsed Disease Diseases of the circulatory system ICD-11: BE2Z
 Disease Info 
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene [2]
Response Summary YTHDF2 knockdown increases mRNA expression levels of MAP2K4 and HPK/GCK-like kinase HGK (MAP4K4) via stabilizing the mRNA transcripts, which activate MAPK and NF-Kappa-B signaling pathways, which promote the expression of proinflammatory cytokines and aggravate the inflammatory response in LPS-stimulated RAW 264.7 cells.
Target Regulation Down regulation
Responsed Disease Inflammatory response ICD-11: MG46
 Disease Info 
Pathway Response MAPK signaling pathway hsa04010
In-vitro Model RAW 264.7 Mouse leukemia Mus musculus CVCL_0493
Diseases of the circulatory system [ICD-11: BE2Z]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary YTHDF2 regulates the stability of MAP2K4 and HPK/GCK-like kinase HGK (MAP4K4) mRNAs.This study identified that dasatinib and quercetin alleviate LPS-induced senescence in HUVECs via the TRAF6-MAPK-NF-Kappa-B axis in a YTHDF2-dependent manner, providing novel ideas for clinical treatment of age-related cardiovascular diseases.
Responsed Disease Diseases of the circulatory system [ICD-11: BE2Z]
Target Regulator YTH domain-containing family protein 2 (YTHDF2) READER
 Regulator Info 
Inflammatory response [ICD-11: MG46]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [2]
Response Summary YTHDF2 knockdown increases mRNA expression levels of MAP2K4 and HPK/GCK-like kinase HGK (MAP4K4) via stabilizing the mRNA transcripts, which activate MAPK and NF-Kappa-B signaling pathways, which promote the expression of proinflammatory cytokines and aggravate the inflammatory response in LPS-stimulated RAW 264.7 cells.
Responsed Disease Inflammatory response [ICD-11: MG46]
Target Regulator YTH domain-containing family protein 2 (YTHDF2) READER
 Regulator Info 
Target Regulation Down regulation
Pathway Response MAPK signaling pathway hsa04010
In-vitro Model RAW 264.7 Mouse leukemia Mus musculus CVCL_0493
References
Ref 1 Senolytics Cocktail Dasatinib and Quercetin Alleviate Human Umbilical Vein Endothelial Cell Senescence via the TRAF6-MAPK-NF-KappaB Axis in a YTHDF2-Dependent Manner. Gerontology. 2022;68(8):920-934. doi: 10.1159/000522656. Epub 2022 Apr 25.
Ref 2 m6A Reader YTHDF2 Regulates LPS-Induced Inflammatory Response. Int J Mol Sci. 2019 Mar 15;20(6):1323. doi: 10.3390/ijms20061323.